MedPath

ENZYCHEM LIFESCIENCES CORPORATION

🇰🇷South Korea
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

10

Active:0
Completed:8

Trial Phases

3 Phases

Phase 1:4
Phase 2:4
Not Applicable:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials

Phase 1
4 (40.0%)
Phase 2
4 (40.0%)
Not Applicable
2 (20.0%)

Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis

Phase 2
Not yet recruiting
Conditions
Atopic Dermatitis
Interventions
Drug: Placebo EC-18
First Posted Date
2024-07-05
Last Posted Date
2024-11-08
Lead Sponsor
Enzychem Lifesciences Corporation
Target Recruit Count
150
Registration Number
NCT06487000

Prevention of COVID-19 Infection to Severe Pneumonia or ARDS

Phase 2
Conditions
Covid19 Pneumonia
Interventions
Drug: Placebo
First Posted Date
2020-09-29
Last Posted Date
2021-06-10
Lead Sponsor
Enzychem Lifesciences Corporation
Target Recruit Count
60
Registration Number
NCT04569227
Locations
🇺🇸

Lincoln Medical Center, Bronx, New York, United States

🇺🇸

Kent County Memorial Hospital, Warwick, Rhode Island, United States

To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia

Phase 2
Completed
Conditions
COVID-19
Interventions
Drug: Placebo EC-18
First Posted Date
2020-08-05
Last Posted Date
2022-02-10
Lead Sponsor
Enzychem Lifesciences Corporation
Target Recruit Count
63
Registration Number
NCT04500132
Locations
🇰🇷

Chungbuk National University Hospital, Cheongju-si, Korea, Republic of

EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation

Phase 2
Completed
Conditions
Stomatitis
Interventions
Drug: Placebo
First Posted Date
2017-06-27
Last Posted Date
2023-07-27
Lead Sponsor
Enzychem Lifesciences Corporation
Target Recruit Count
105
Registration Number
NCT03200340
Locations
🇺🇸

Veterans Affairs Long Beach Health Care System, Long Beach, California, United States

🇺🇸

UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States

and more 16 locations

Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer

Phase 1
Completed
Conditions
Febrile Neutropenia
Interventions
First Posted Date
2017-04-07
Last Posted Date
2023-08-15
Lead Sponsor
Enzychem Lifesciences Corporation
Target Recruit Count
28
Registration Number
NCT03104595
Locations
🇰🇷

National Cancer Center, Gyeonggi-do, Korea, Republic of

🇰🇷

Yonsei University Health System Severance Hospital, Seoul, Korea, Republic of

🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.